Background: Our previous results showed that nitric oxide (NO) and bradykinin (BK) mediate the arthritis induced by *Bothrops jararaca* venom (BjV) in rabbits. In this study, we investigated the contribution of each receptor of BK as well as the inter-relationship between NO and eicosanoids in BjV-induced arthritis.

Methods: The arthritis was induced in rabbits with 16 μg of BjV injected intra-articularly. Prostaglandin E$_2$ (PGE$_2$), thromboxane B$_2$ (TxB$_2$), leukotriene B$_4$ (LTB$_4$) (radioimmunoassay) and nitrite/nitrate concentrations (NO$_2$/NO$_3$) (Griess reaction) were evaluated in the synovial fluid 4 h later. The animals were prior treated with NO synthase inhibitor (L-NAME; 20 mg/kg/day for 14 days), the B2 antagonist of BK (HOE-140) and the B1 antagonist of BK (des-Arg$^9$(Leu)$^8$-bradykinin), both at a dose of 0.3 mg/kg, 30 min prior to the venom injection.

Results: Data show that L-NAME and HOE-140 treatment were equally able to reduce PGE$_2$ and NO$_2$/NO$_3$ levels without interfering with TxB$_2$ and LTB$_4$ production. On the contrary, the B1 antagonist of BK inhibited TxB$_2$ and LTB$_4$ production, and did not alter PGE$_2$ and NO metabolites levels in the inflamed joint.

Discussions: The results presented clarify the contribution of the kinin system, mainly through the B2 receptor, to the local inflammatory response induced by BjV, as well as its positive interaction with PGE$_2$ and NO production.

Key words: *Bothrops jararaca* venom, Inflammatory reaction, Arthritis, Bradykinin, Nitric oxide, Eicosanoids

Introduction

Endogenous nitric oxide (NO) has been described as a pro-inflammatory molecule showing interactions with cytokines$^{1-3}$ and inflammatory products of the cyclooxygenase pathway.$^{4-10}$ Studies have shown that NO increases interleukin-1β and eicosanoid products, which may result in an exacerbated inflammatory response.$^2,3$ In addition, inhibition of NO biosynthesis by an L-arginine antagonist reduced prostaglandin E$_2$ (PGE$_2$) production in different models of inflammatory reactions *in vivo*.$^{11-13}$

Additionally, bradykinin (BK) and NO have been implicated on eicosanoids and cytokine secretions in several experimental inflammatory processes.$^8,12,13-15$ BK acts on the acid arachidonic metabolism via both phospholipase A$_2$$^{16}$ and phospholipase C$^{17}$ activation. Also, BK is known to release NO from various cells, including polymorphonuclear$^{18}$ and endothelial cells at the site of injury.$^{19}$

The acute inflammatory reaction induced by *Bothrops jararaca* venom (BjV) is determined by oedema and leukocyte influx.$^{20-22}$ These effects are mediated by histamine, serotonin, products of arachidonic acid metabolism, platelet-activating factor and factors derived from complement system.$^{20-22}$ The eicosanoids contribution is relevant to oedema formation and leukocyte recruitment during BjV-induced pleurisy and air-pouch inflammatory reaction.$^{21,22}$ Recently, to determine the participation of kinins and NO in the local inflammatory reaction induced by BjV, we developed an experimental model of arthritis by injecting the venom intra-articularly. The findings that B2 BK antagonist (HOE-140) and NO synthase inhibitor (L-NAME) treatment greatly reduced the cellular influx and protein leakage in the arthritis induced by BjV clearly implicate kinins and NO in this phenomenon.$^{23}$

Since eicosanoids, BK and NO are important mediators involved in the inflammatory reaction evoked by BjV, and since there is strong evidence regarding the interaction between these mediators on different models of the inflammatory process, the aim of this study was to evaluate the participation of each receptor of BK in NO and eicosanoid production in the acute inflammatory response evoked by BjV.
Material and methods

Induction of arthritis

The Animal Ethics Committee of COBEA (Brazilian College of Experimental Animals) approved all experimental procedures, performed on animals in accordance with procedures set by The Universities Federation for Animals Welfare. The arthritis was induced in the knee joint of male New Zealand White rabbits (2 kg) by the injection of BjV provided by the Laboratory of Herpetology, Butantan Institute, Brazil (16 µg diluted in 0.5 ml of saline). The venom was filtered in sterilising membrane (ester cellulose filter, 0.22 µm pore size; Millipore, São Paolo, Brazil) before joint injection. The contralateral joint was injected with the same amount of bovine serum albumin (Sigma, St Louis, MO, USA). The amount of protein present in BjV or BSA solution was spectrophotometrically assessed and the equivalent protein concentration was injected in each joint. Four hours after intra-articular challenge, the animal was anaesthetised with a mixture of xylazine (5 mg/kg; Bayer, São Paolo, Brazil) associated with ketamine (50 mg/kg; Parke Davis, São Paolo, Brazil) by intramuscular injection and killed by intravenous injection of 2.0 ml of 20% KCl solution. Immediately after the sacrifice, 2 ml of saline containing ethylenediamine tetraacetic acid (1 mg/ml) was injected into the knee joint. Synovial fluid was aspirated, the joint was opened and the remainder of the synovial fluid was recovered and stored at -70°C.

Pharmacological treatments

A group of animals were randomly treated with L-NAME (Sigma), 20 mg/kg/day mixed with drinking water, administered for 2 weeks prior to the induction of arthritis. Treatments with 0.3 mg/kg of B1 or B2 BK antagonists des-Arg⁹[Leu⁸]-bradykinin (Sigma) and HOE-140 (Hoechst, Frankfurt, Germany), respectively, were performed subcutaneously, 30 min before the venom injection. Control animals received an equivalent volume of sterile saline by the same route.

Determination of total NO₂⁻/NO₃⁻ levels in the synovial fluid

The concentration of the total amount of nitrate and nitrite (NO₂⁻/NO₃⁻) anions (stable NO breakdown products in vivo) present in the synovial fluid samples collected 4 h after venom injection was determined by Griess reaction. The absorbance was monitored at 546 nm.

Determination of eicosanoids in the synovial fluid

PGE₂, thromboxane B₂ (TxB₂), leukotriene B₄ (LTB₄) levels were assayed in the synovial fluid collected 4 h after venom injection using commercial kits (NEN Life Science products, Boston, MA, USA) as previously described. The competitive binding radioimmunoassays were performed in polypropylene tubes with the reagents diluted in phosphate-buffered saline (pH 6.8) with gelatine and thimerosal. One hundred microlitres of each unknown samples, of tracers (¹²⁵I-PGE₂ and ¹²⁵I-TxB₂ or ³H-LTB₄), and of rabbit antiserum to each eicosanoids were combined and incubated overnight at 8°C for LTB₄ determination, and were then incubated for 2 h at 25°C in a water bath for PGE₂ and TxB₂ determinations. Unbound radiolabelled PGE₂ and TxB₂ was removed by the addition of 250 µl of donkey anti-rabbit serum coated onto magnetisable polymer particles, and LTB₄ was removed by the addition of 250 µl of 2% charcoal suspension coated with 0.4% dextran to the tubes. After centrifugation, the residual bound activity was measured in each tube by counting ¹²⁵I-PGE₂ and ¹²⁵I-TxB₂ or ³H-LTB₄ in a γ-scintillation counter, and ³H-LTB₄ in a β-scintillation counter. Cross-reactivities of the antiserum with other eicosanoids were below 0.05%. The assay sensitivities were 1.25–160 pg/tube (PGE₂), and 1.6–200 pg/tube (LTB₄).

Statistics

Results are expressed as mean ± standard error of mean. Results were analysed by Student’s t-test or by repeated-measures analysis of variance. When appropriate, the data were analysed by the Newman-Keuls test. The chosen level of significance was 0.05.

Results

Eicosanoids and NO₂⁻/NO₃⁻ levels in the synovial fluid

The synovial fluid collected from animals pre-treated with L-NAME, HOE-140 and des-Arg⁹[Leu⁸]-bradykinin and intra-articularly injected with venom, and that from respective controls, was extracted to PGE₂, LTB₄ and TxB₂. The determinations were performed by radioimmunoassay. NO₂⁻/NO₃⁻ levels in diluted joint wash were also determined by Griess reaction. Figure 1A shows the PGE₂ level measured in the synovial fluid obtained 4 h after the BjV. Prior treatment of the rabbits with L-NAME or B2 antagonist of BK HOE-140 significantly reduced it when compared with values obtained in samples from animals, which did not receive pharmacological treatments. It is important to note that des-Arg⁹[Leu⁸]-bradykinin treatment did not interfere with the production of PGE₂. On the contrary, levels of LTB₄ and TxB₂ (represented in Fig. 1B and Fig. 1C, respectively) exhibited a different pattern of alteration. They were not altered after treatment with L-NAME or HOE-140, but they were greatly reduced...
after pre-treatment with the B1 antagonist of BK des-Arg<sub>9</sub>[Leu<sub>8</sub>]-bradykinin. Also, values observed in samples from B1 antagonist-treated animals were significantly lower than that obtained in control animals. At the fourth hour after the injection of BSA, the contralateral joint exhibited low levels of the eicosanoids, similar to the observed in the saline-injected joint (data not shown).<sup>12,26</sup>

Similar to the observed pattern of alteration promoted in PGE<sub>2</sub> production, the level of the total amount of the NO metabolites (NO<sub>2</sub>/NO<sub>3</sub>) (Fig. 1D) was significantly reduced in the synovial fluid collected from L-NAME-treated and HOE-140-treated animals when compared with the level observed in control animals. Differently, the treatment with the B1 antagonist of BK, des-Arg<sub>9</sub>[Leu<sub>8</sub>]-bradykinin, did not affect NO production in the joint, which exhibited values of NO<sub>2</sub>/NO<sub>3</sub> obtained 4 h after BjV injection equivalent to those found in control animals.

**Discussion**

The data presented in this paper regarding BjV local effects corroborate the positive cross-talk between BK, NO and the cyclooxygenase (COX) product PGE<sub>2</sub> described in the inflammatory reaction induced by other different agents<sup>8,12,13</sup> and additionally show the main participation of the B2 BK receptor in this axis. This last observation is in accordance with recent experimental studies in rats that demonstrated HOE-140 treatment reduced the oedema induced by local injection of *Bothrops lanceolatus* snake venom and abolished the hyperalgesic effect of BjV.<sup>27,28</sup> Additionally, the employment of specific receptor antagonists and enzymatic inhibitors in experimental studies has demonstrated the participation of BK receptors and COX metabolites on the inflammatory process evoked by BjV through measurement of its symptomatic effects such as oedema,<sup>20,21,29</sup> leukocyte recruitment,<sup>21,22,29</sup> and pain.<sup>28</sup> However, in the experimental model employed in this study, it was possible to establish the link between each mediator involved in the kinin/NO/COX axis at the inflammatory site after pharmacological treatments.

We have clearly demonstrated the contribution of the kinin system, via the B2 receptor, on NO production, with subsequent stimulation of PGE<sub>2</sub> secretion. Also, our results showed that the B2 receptor and NO do not participate in LTB<sub>4</sub> and TXB<sub>2</sub> secretions, which were affected by inhibition of the B1 receptor. These conclusions are demonstrated by the following observations: (1) HOE-140 and L-NAME treatments equally abolished the inflammatory reaction,<sup>23</sup> PGE<sub>2</sub> and NO<sub>2</sub>/NO<sub>3</sub> levels without interfering with LTB<sub>4</sub> or TXB<sub>2</sub> production; and (2) alternatively, des-Arg<sub>9</sub>[Leu<sub>8</sub>]-bradykinin treatment did not alter the PGE<sub>2</sub> and NO metabolites, and greatly reduced LTB<sub>4</sub> and TXB<sub>2</sub> secretions. It is important to note that our previous results showed that the NO synthase inhibitor (L-NAME) and the B2 receptor antagonist of BK (HOE-140) treatments promoted a great reduction of the leukocyte influx (90% of the control animals) to the articular cavity.<sup>23</sup> These data associated with the
verified low levels of LTB\textsubscript{4} in the joint, suggest the participation of other(s) chemotactant(s) in this phase of BjV inflammatory reaction. Recent experimental studies have demonstrated that Bothrops snake venoms activate the complement system, with a consequent contribution of its metabolites on leukocyte recruitment.\textsuperscript{22,30} The participation of the complement system, BK and NO has been described in several models of inflammation.\textsuperscript{31,32} The possibility that the complement system participates in or may be affected by BK/NO cascade in the bothropic envenomation will be further investigated. In addition, the treatment with the B1 receptor antagonist of BK, which promoted reduction of LTB\textsubscript{4}, was less effective than HOE-140, promoting 40% of reduction in the cellular influx to the inflamed area (data not shown).

In conclusion, our results suggest that the NO generation in arthritis induced by BjV is produced mainly after BK stimulation through B2 receptors. Also, the endogenous release of NO enhances COX activity with further increase of PGE\textsubscript{2} production, demonstrating the inter-relation between the kinins system with NO and PGE\textsubscript{2} in the BjV inflammatory process.

This paper, together our previous results,\textsuperscript{23} would be useful to pharmacological interventions to modulate the imminent inflammatory response evoked by BjV, which is not neutralised by specific antivenom.

ACKNOWLEDGEMENTS. The authors thank Maria de Fatima de Almeida and Maria Aurora Gomes da Silva for technical assistance. This work was supported by FAPESP grants #99/0149–5.

References

1. Kelner MJ, Uglik SF. Mechanism of prostaglandin E\textsubscript{2} release and increase in PGE/PGE\textsubscript{2} isomerase activity by PGE\textsubscript{2} involvement of nitric oxide. Arch Biochem Biophys 1994; 312: 240–245.
2. Inoue T, Fukusaki K, Morimoto S, Koh E, Ogihara T. Nitric oxides mediates interleukin-1-induced prostaglandin E\textsubscript{2} production by vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 194: 420–424.
3. Corbett JA, Kwon G, Turk J, McDaniel ML. II-beta induces coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767–13770.
4. Milano S, Arcoelo E, Dieli M, D’Agostino R, D’Agostino P, De Nucci G, Cillari E. Prostaglandin E\textsubscript{2} regulates inducible nitric oxide synthase in the murine macrophage cell line J774. Prostaglandins 1995; 49: 105–115.
5. Molina HE, Lledo A, Guaza C. Evidence for cyclooxygenase activation by nitric oxide astrocytes. Glia 1995; 15: 167–172.
6. Davidson ST, Baker PN, Laughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 1995; 77: 274–285.
7. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide: an in vitro analysis. Br J Pharmacol 1995; 114: 1171–1178.
8. Szwiersko TA, Mitchell JA, Warner TD, Botton RM, Vane JR. Co-induction of prostaglandin synthase and cyclooxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114: 1355–1342.
9. Tetsuka T, Dafina-Iken D, Srivastava SK, Baier LD, DuMaine J, Morrison AR. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E\textsubscript{2}, negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci USA 1994; 91: 12168–12172.
10. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1997; 94: 7240–7244.
11. Verossimo de Mello SB, Novaes GS, Laurindo IM, Maciel FM, Cossermelli W. NOs inhibition influences eicosanoids and interleukin 1 production in experimental arthritic joint. Inflamm Res 1997; 46: 72–77.
12. Palacios FAS, Novaes GS, Guzzo ML, Laurindo IM, Mello SBV. Interrelationship of kinin system, nitric oxide and eicosanoids in the antigen induced arthritis in rabbits. Mediat Inflamm 1999; 8: 249–255.
13. Cazan LJ, Garcia-Novelli A, de Ponce LA, Sosa D, Simonetti LG. Bradykinin stimulates platelet-released nitric oxide. Eur J Pharmacol 1995; 292: 287–290.
14. Asahi K, Tada K, Mori M, Miyazaki T. Nitric oxide-mediated suppression of rat gastric ulcer and dyspepsia in vivo. J Pharmacol Exp Ther 1997; 281: 1141–1146.
15. Szwiersko TA, Mitchell JA, Warner TD, Vane JR. Co-induction of nitric oxide synthase and cyclooxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114: 1171–1178.

Received 10 September 2001
Accepted 16 October 2001

References